Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 5Myeloproliferative Disorders 2Myelodysplastic Syndromes 1Leukemia, Monocytic, Acute 1

Interventions

fludarabine 17Cyclophosphamide 15Specimen Handling 14Biopsy 12fludarabine phosphate 11Melphalan 10Cytarabine 10Busulfan 10Mycophenolic Acid 9venetoclax 8Whole-Body Irradiation 8Tacrolimus 8decitabine and cedazuridine drug combination 7Granulocyte Colony-Stimulating Factor 7Injections 6Cyclosporine 6Azacitidine 6Stem Cell Transplantation 5Sirolimus 5Filgrastim 5X-Rays 4Thiotepa 4Peripheral Blood Stem Cell Transplantation 4Idarubicin 4CPX-351 4ruxolitinib 3Magnetic Resonance Spectroscopy 3Hematopoietic Stem Cell Transplantation 3Decitabine 3treosulfan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × Liposomes × 30 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡